Researchers at Spain’s Universidad Politécnica de Madrid (UPM) and start-up AURA Innotive Robotics have developed a new robotic system called OSCANN Desk, designed to accurately analyse eye movements for detecting neurodegenerative diseases such as Parkinson’s disease and dementia.

The fast yet non-invasive technology leverages imaging processing and machine learning to deliver objective brain functioning data, which is expected to aid in early diagnosis and customised treatments.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

OSCANN Desk can be used in a healthcare centre, where personnel will perform certain calibration and clinical tests that take around one minute each.

“The fast yet non-invasive technology leverages imaging processing and machine learning to deliver objective brain functioning data, which is expected to aid in early diagnosis and customised treatments.”

The medical device is attached to a patient’s anatomy to measure the eye movement while they look at the stimulus displayed on a monitor.

These tests were used by the researchers to create pathology models.

The team then applied machine learning techniques to identify similarities and differences amongst more than 500 variables of eye movement. According to the team, some symptoms can be objectively measured using a similar approach.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The tests were already applied for Parkinson’s and Alzheimer’s disease, diverse dementias, mild cognitive impairment and multiple sclerosis, among others.

Furthermore, the researchers are working towards leveraging the tests for other conditions, including autistic spectrum disorders, epilepsy, alcoholism, migraines, depression, bipolar disorder and diabetes.

OSCANN Desk is being studied in a clinical trial at six Spanish hospitals in Spain, with plans to bring the device to the country’s HM Hospitals, particularly for the HM CINAC’s Memory Disorders Unit at the Hospital Universitario HM Madrid.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact